Development and validation of reversed phase high performance liquid chromatographic method for determination of moxonidine in the presence of its impurities

Journal of Pharmaceutical and Biomedical Analysis

Volumn 59, Issue 1, 2012, Pages 151-156

  Milovanović, Svetlana ^a   Otašević, Biljana ^b   Zečević, Mira ^b   Živanović, Ljiljana ^b   Protić, Ana ^b  

^a Medicines and Medical Devices Agency of Serbia   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Central composite design; Impurities; Method validation; Moxonidine; Reversed phase high performance liquid chromatography

Indexed keywords

METHANOL; MOXONIDINE; PHOSPHATE BUFFERED SALINE; POTASSIUM DIHYDROGEN PHOSPHATE;

ARTICLE; CHROMATOGRAPHY; DRUG IMPURITY; FLOW RATE; PH; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TABLET FORMULATION; TEMPERATURE;

ANTIHYPERTENSIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; DRUG CONTAMINATION; IMIDAZOLES; LIMIT OF DETECTION; MOLECULAR STRUCTURE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SOLUTIONS; TABLETS; TIME FACTORS;

EID: 82255183033     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.09.029     Document Type: Article

References (10)

1. 1-imidazoline receptor agonist. J. Cardiovasc. Pharm. 1996, 27:S26-S37.
2. European Pharmacopoeia 2011, Council of Europe, Strasbourg, France. 7th ed.
3. British Pharmacopoeia 2011, British Pharmacopoeia Commission, The Stationery Office (TSO), London, United Kingdom.
4. Zhao L., Ding L., Wei X. Determination of moxonidine in human plasma by liquid chromatography-electrospray ionisation-mass spectrometry. J. Pharm. Biomed. Anal. 2006, 40:95-99.
5. Rudolph M., Janssen W., Strassner M. Determination of moxonidine (BDF 5895) in plasma by gas chromatography-negative ion chemical ionization mass spectrometry. J. Pharm. Biomed. Anal. 1992, 10:323-328.
6. Jocić B., Zečević M., Živanović Lj., Protić A., Jadranin M., Vajs V. Study of forced degradation behavior of Eletriptan hydrobromide by LC and LC-MS and development of stability-indicating method. J. Pharm. Biomed. Anal. 2009, 50:622-629.
7. Ferreira S.L.C., Brun R.E., Paranhos da Silva E.G., Lopes dos Santos W.N., Quintella C.M., David J.M., Bittencourt de Andrade J., Breitkreitz M.C., Jardim I.C.S.F., Neto B.B. Statistical designs and response surface techniques for the optimization of chromatographic systems. J. Chromatogr. A 2007, 1158:2-14.
8. Jocić B., Zečević M., Živanović Lj., Ličanski A. A chemometrical approach to optimization and validation of an HPLC assay for rizatriptan and its impurities in tablets. Anal. Lett. 2007, 40:2301-2316.
9. Moffat A.C., Osselton D., Widdop B. Clarke's Analysis of Drugs and Poisons 2004, Pharmaceutical Press, London. third ed.
10. ICH topic Q2(R1) Validation of analytical procedures: text and methodology. Fed. Regist. 1997, 62:27463-27467. (addendum incorporated 2005).